October 28, 2021

New Multifocal Contact Lenses for Presbyopia and MiSight® 1 day Study
Seven-Year Data Exemplify Innovation & Impact; Expected to Draw
Widespread Interest from Eye Care Community

SAN RAMON, CALIF., October 28, 2021—When thousands of eye care professionals gather next week for the 2021 American Academy of Optometry annual meeting, they will be greeted by a series of CooperVision introductions and announcements that represent significant advancements in contact lens design, evidence-based research, and clinical tools.

The company plans to launch new multifocal contact lens options for the U.S. market in Boston, including MyDay® daily disposable multifocal that expands the popular premium silicone hydrogel 1 day family. It will also share findings from multiple research programs, including highly anticipated seven-year myopia control data from the CooperVision MiSight® 1 day* contact lens clinical trial.

“Since springtime, we have heard customers and colleagues saying how much they’ve been looking forward to Academy—for the education, the science, the products, and of course the people,” said Melissa Kiewe, Vice President of Marketing (North America) for CooperVision. “We can’t wait to share how CooperVision innovation and partnerships with the optometry community are taking on presbyopia like never before, slowing the progression of myopia, and helping practices extend and deepen their patient relationships.”

Introducing New Multifocal Contact Lenses

Leveraging its deep expertise in optical design and prescribing practices, CooperVision has created a new multifocal soft contact lens, ideal for patients who are experiencing any level of presbyopia. MyDay® daily disposable multifocals have been developed to help eye care professionals (ECPs) in every practice setting.

They are the first lenses to feature the Binocular Progressive System, an innovative 3-ADD approach that caters to all levels of presbyopia with simplified fitting, optimal visual acuity at all distances,1 and a comfortable wearing experience. ECPs can successfully fit 98% of patients with two pairs of MyDay® multifocal lenses or fewer when following the fitting guide.1,2

As part of the U.S. launch, which includes a kick-off on Thursday, November 4, at 5 p.m., CooperVision will premiere the companion marketing campaign. By visiting CooperVision’s booth, Academy attendees can insert themselves into the program, “Game On, Presbyopia,” celebrating how the condition has finally met its match in the form of for MyDay® multifocal.

During Academy 2021, CooperVision Specialty EyeCare will introduce Decentered Multifocal Optics for its Onefit™ and Onefit™ MED+ scleral contact lenses. The upgraded design—which is supported by a user-friendly online fitting tool—enables practitioners to reposition the multifocal optics to align with the visual axis, which is key to achieving outstanding visual results and superior subjective vision.

Extensive Scientific Program on Presbyopia, Myopia Management and Contact Lens Comfort

For decades, Academy has hosted one of the most extensive collections of new optometric research worldwide, and this year looks to carry on that tradition. CooperVision’s evidence-based papers and posters reflect a gamut of topics that underpin the contact lens industry’s evolution, with implications for clinical practice and product development. Of particular focus are works regarding outcomes in long-term MiSight® 1 day contact lens wearers after cessation, multifocal contact lens success among presbyopes, and insights into contact lens comfort dynamics.

Academy will mark the first public reveal of seven-year data from the CooperVision MiSight® 1 day clinical trial, the world’s longest-running soft contact lens study for myopia control. In what is expected to be a room-filling paper presentation on Friday, November 5, at 10 a.m., attendees will learn how accumulated myopia control treatment in children was affected when lens wear was discontinued. A companion work compares mean axial length growth rates to predicted rates using established myopia eye growth models, further validating MiSight® 1 day’s efficacy and the company’s commitment to extensive myopia control research.

New research explores how CooperVison’s MyDay® daily disposable multifocal contact lenses achieve patient satisfaction, visual performance, and binocularity across low, medium and high ADD powers, helping meet the needs of emergent to advanced presbyopes. A related work presents data from two randomized clinical trials that illustrate how the innovative Binocular Progressive System supports a high rate of fitting success for MyDay® multifocal among habitual multifocal contact lens wearers.1,2 Looking beyond soft contact lenses, another study examines how wearing a non-dominant multifocal scleral lens design in both eyes show better near visual acuity and stereopsis compared with other combinations.

A leader in advancing the science of contact lens comfort, CooperVision will delve into several studies during Academy that enhance clinical practice. One centers on proactive management of symptomatic lens wearers, finding that switching to a new silicone hydrogel daily disposable lens had more impact than treatment of mild tear film and/or ocular tissue anomalies. Another demonstrates how to identify neophyte wearers who are at greater risk of persistent or worsening discomfort within the first one to three months, leading to better early management and reducing drop out. A third follows symptomatic adults who resume soft contact lens wear after temporary discontinuation, discerning patterns of recurring symptoms to help prevent subsequent drop out.

Visit CooperVision at Academy 2021

To learn more about CooperVision products, research, and practice tools, stop by American Academy of Optometry Booth #613 from November 3-5, 2021, or visit CooperVision.com.

* Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.


1 CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study UK with MyDay® multifocal; n=104 habitual multifocal contact lens wearers; CVI data on file 2021.

2 CVI data on file, 2021. Prospective, subject-masked, randomized, bilateral, two-week dispensing study at 5 US sites with MyDay® daily disposable multifocal; n=58 habitual multifocal contact lens wearers.

# # #

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com

Media Contact
Maggie Munley, Counselor, McDougall Communications
maggie@mcdougallpr.com or +1-585-434-2149